Evaluation of atezolizumab immunogenicity: Clinical pharmacology (part 1)
Abstract Baseline patient characteristics and prognostic factors are important considerations in oncology when evaluating the impact of immunogenicity on pharmacokinetics (PK) and efficacy. Here, we assessed the impact of anti‐drug antibodies (ADA) on the PK of the immune checkpoint inhibitor atezol...
Сохранить в:
| Главные авторы: | , , , , , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Wiley
2022-01-01
|
| Серии: | Clinical and Translational Science |
| Online-ссылка: | https://doi.org/10.1111/cts.13127 |
| Метки: |
Нет меток, Требуется 1-ая метка записи!
|